Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
After Phase 3 results show major hair regrowth gains
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The submission is backed by positive results from the Phase 3 AFFIRM study
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Subscribe To Our Newsletter & Stay Updated
